Equillium Inc
NASDAQ:EQ

Watchlist Manager
Equillium Inc Logo
Equillium Inc
NASDAQ:EQ
Watchlist
Price: 0.7549 USD -3.22% Market Closed
Market Cap: 26.7m USD

Equillium Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Equillium Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Equillium Inc
NASDAQ:EQ
Net Issuance of Common Stock
$166k
CAGR 3-Years
-82%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Issuance of Common Stock
-$1.5B
CAGR 3-Years
-29%
CAGR 5-Years
-19%
CAGR 10-Years
-13%
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Common Stock
-$728m
CAGR 3-Years
-25%
CAGR 5-Years
14%
CAGR 10-Years
18%
Amgen Inc
NASDAQ:AMGN
Net Issuance of Common Stock
-$200m
CAGR 3-Years
66%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Common Stock
-$1.1B
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Common Stock
-$1.1B
CAGR 3-Years
N/A
CAGR 5-Years
-78%
CAGR 10-Years
N/A

Equillium Inc
Glance View

Market Cap
26.7m USD
Industry
Biotechnology

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.

EQ Intrinsic Value
0.847 USD
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Equillium Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
166k USD

Based on the financial report for Sep 30, 2024, Equillium Inc's Net Issuance of Common Stock amounts to 166k USD.

What is Equillium Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-70%

The average annual Net Issuance of Common Stock growth rates for Equillium Inc have been -82% over the past three years , -70% over the past five years .

Back to Top